COST EFFECTIVENESS OF ZOLEDRONIC ACID (ZOL) IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER RECEIVING ADJUVANT LETROZOLE FROM GERMAN AND ITALIAN PERSPECTIVES
Author(s)
Xue M1, Fishman P2, Botteman M11Pharmerit International, Bethesda, MD, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Presentation Documents
OBJECTIVES: In the ZO-FAST trial, postmenopausal women with early breast cancer (pmBCa) and a bone mineral density (BMD) T-score ≥–2 and receiving adjuvant Letrozole (2.5 mg/day) were randomized to either immediate ZOL (4 mg/6 months) treatment (“Upfront ZOL”) or to the same therapy but only when BMD T-score decreased to
Conference/Value in Health Info
2012-06, ISPOR 2012, Washington, D.C., USA
Value in Health, Vol. 15, No. 4 (June 2012)
Code
PCN67
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology